CN108379305A - 桑黄水提物在抗尿酸中的应用 - Google Patents
桑黄水提物在抗尿酸中的应用 Download PDFInfo
- Publication number
- CN108379305A CN108379305A CN201810370531.8A CN201810370531A CN108379305A CN 108379305 A CN108379305 A CN 108379305A CN 201810370531 A CN201810370531 A CN 201810370531A CN 108379305 A CN108379305 A CN 108379305A
- Authority
- CN
- China
- Prior art keywords
- phellinus
- extract
- uric acid
- water
- water extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000123107 Phellinus Species 0.000 title claims abstract description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 239000000284 extract Substances 0.000 title claims abstract description 28
- 229940116269 uric acid Drugs 0.000 title claims abstract description 27
- 239000000126 substance Substances 0.000 claims abstract description 10
- 239000006286 aqueous extract Substances 0.000 claims abstract description 9
- 239000011259 mixed solution Substances 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 8
- 239000006228 supernatant Substances 0.000 claims abstract description 8
- 238000009835 boiling Methods 0.000 claims abstract description 5
- 238000003756 stirring Methods 0.000 claims abstract description 4
- 238000004949 mass spectrometry Methods 0.000 claims abstract 2
- 239000007788 liquid Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical group N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 28
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 21
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 abstract description 16
- 201000005569 Gout Diseases 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 13
- 229960001338 colchicine Drugs 0.000 abstract description 6
- 230000008021 deposition Effects 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 16
- 239000003814 drug Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 201000001431 Hyperuricemia Diseases 0.000 description 6
- 206010023232 Joint swelling Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000001503 joint Anatomy 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 108010093894 Xanthine oxidase Proteins 0.000 description 4
- 102100033220 Xanthine oxidase Human genes 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000002398 materia medica Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000218213 Morus <angiosperm> Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- -1 triterpene acids Chemical class 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 240000004507 Abelmoschus esculentus Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 241000723375 Colchicum Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000123113 Phellinus igniarius Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 102000003898 interleukin-24 Human genes 0.000 description 1
- 108090000237 interleukin-24 Proteins 0.000 description 1
- 230000003903 intestinal lesions Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000001751 uricolytic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种桑黄水提物在抗尿酸中应用，该桑黄水提物主要包含质荷比为1015.0270、1029.2048道尔顿的两种物质，该两种物质质谱检测谱峰强度分别为60％和100％；该桑黄醇提物制备方法如下：取生长于长白山地区的桑黄打碎成粉末；将桑黄粉末加入水搅拌均匀后，放在沸水浴中煮2h得到混合溶液；将混合溶液冷却，超速离心，取上清；将上清进行过滤得桑黄水提物，121℃高压灭菌得到桑黄水提物。本发明的桑黄水提物与秋水仙碱相比，在减少关节腔中尿酸沉积方面效果更好，因此可以利用桑黄水提物降低体内的尿酸含量，以达到治疗痛风的目的。
Description
技术领域
本发明属于桑黄提取物及其应用技术领域，具体涉及一种桑黄水提物能及其抗尿酸应用。
背景技术
痛风是一种常见的与关节疼痛、疲劳和高烧相关的关节炎疾病。尿酸水平的升高是痛风的生化基础，由于灵长类在进化过程中丢失了尿酸分解酶，不能将嘌呤代谢终产物(尿酸)进一步分解成可溶于水的尿囊素，导致血中尿酸增高，从而引起尿酸盐在组织中沉积，致使痛风成为人类较特殊的疾病。根据研究，痛风的患病率为2％，尤其是40岁以上伴有代谢综合征的男性为多发人群。
一般认为，痛风是由慢性高尿酸血症(血尿酸[UA]水平>6.8mg/dL)引起的，尿酸钠沉积在关节内，无症状性高尿酸血症是痛风发生的前期状态，痛风必伴有高尿酸血症。UA是黄嘌呤氧化酶(XO)催化下嘌呤分解代谢的最终产物，也是痛风的主要临床生化指标。随着UA产生，细胞内氧化增加。氧化应激源自大量高反应性分子，导致氧化和抗氧化系统失衡，最终破坏细胞功能。相反，UA将痛风的症状与炎症反应联系起来。尿酸钠晶体刺激单核细胞产生肿瘤坏死因子α(TNF-α)和白细胞介素-1(IL-1β)并激活内皮细胞。
根据其发病机制，痛风可以通过降低血清中UA的含量和溶解尿酸盐晶体来治疗。别嘌呤醇(AL)用于治疗高尿酸血症，但对治疗急性痛风无效；非甾体抗炎药(NSAIDs)主要通过降低环氧合酶的水平发挥其抗炎和镇痛作用；秋水仙碱(Colchicine，COL)是一种从莲子和秋葵种子中分离出来的生物碱，可减少炎症和UA晶体沉积，主要用于治疗急性痛风。然而，非甾体抗炎药会引起肠道病变，并增加肾脏疾病的风险；COL给药轻则导致中性粒细胞减少症和贫血，严重的可能导致惊厥，昏迷，多器官衰竭甚至死亡。因此有必要寻找对痛风的治疗和预防副作用小的新型替代药物。
天然药物由于含有复杂的化合物，因此具有多种生物活性、较好的功效和较少的副作用而成为新型药物的来源。分离自东方生物的槲皮素可降低由oxonate引起的高尿酸血症小鼠的UA，这部分归因于其抑制肝脏XO活性。银杏叶可抑制XO活性，并在MSU晶体诱发的痛风和关节炎模型中显示抗炎作用。而桑黄作为一种传统的中药也已经有千年的历史。
桑黄是珍贵的药用真菌，主要分布于中国东北、华北、西北及四川、云南等地，在日本、韩国、朝鲜等东亚国家也有分布。广义的桑黄属于真菌界、担子菌亚门、层菌纲、锈革孔菌目、锈革孔菌科，又名桑耳、桑臣、桑耳、猢狲眼等。桑黄在中国已经有2000多年的历史，最早见于《神农本草经》中的“桑耳”，随后在《药性论》、《新修本草》中也有记载，特别是明代李时珍的《本草纲目》对桑黄及其药效有明确记载。桑黄只生长在桑树活树上，鉴于只生长在桑树活树上这种特殊的生理状态及受外部环境的制约，自然界中桑黄子实体生长缓慢，较为稀少，虽然能够人工栽培，但所需条件苛刻，获得效率低下，目前难以实现规模化栽培。而液体发酵作为现代发酵工程的产物，具有生产周期短、易于控制、可获得大量细胞产物和代谢物、不受季节气候限制和可自动化控制规模化生产等优点，对获得大量桑黄菌丝体或活性物质具有重要意义。我国真正的野生桑黄属于濒危药材，资源极其稀少且生长缓慢，与其相似的菌株种类和产量较多，在东亚地区尤其是韩国、日本常被当作“桑黄”广泛应用于保健品与药物制剂。
近年来，随着对桑黄的研究不断深入，其活性成分被提取、分离、鉴定，而其药用价值也越来越得到人们的关注。现代研究表明，桑黄的主要活性物质包括多糖、黑色素、过氧化酶、麦角甾醇、芳樟醇、三萜酸、脂肪酸类、芳香酸、原儿茶醛、丁香酸、咖啡酸、柚皮素、樱花亭、香豆素等成分。其中研究最多的是桑黄多糖，其具有抗肿瘤和调节免疫的效果，增强巨噬细胞的吞噬指数和吞噬率，促进B细胞和T细胞的增殖，提高血清中细胞因子TNF-γ的含量，且肿瘤坏死因子的释放和多糖呈剂量依赖性，其抗癌的机理是通过提高抗原与各种免疫识别所需的共刺激分子以及组织相容性复合体分子间的作用，影响了呈现抗原表达过程中所必需的一些细胞表面活性分子来间接调控T-cell调节免疫来对抗癌细胞，而达到抗癌效果。桑黄的热水提取物用在保护肝损伤、治疗肝纤维化方面的研究，以四氯化碳诱导大鼠肝损伤,观察桑黄对血清学和组织学指标的影响。结果显示：桑黄治疗组大鼠肝细胞变性明显减轻,肝组织结构完好；血清氨基酸转移酶水平显著降低，蛋白合成能力增强；血清活性氧显著减少，肝组织超氧化物歧化酶活力提高；血清白细胞介素24水平降低，TNF-α显著增高。研究指出，抗脂质过氧化和调节炎症因子水平是桑黄具有保护肝细胞功能的作用机理，而桑黄能抗肝纤维化的作用机理是桑黄能改善血动力学性能，提高肝区微循环，可诱导提高超氧化物歧化酶(SOD)活性，清除氧自由基，发挥抗脂质过氧化作用。从药用真菌桑黄发酵液中分离纯化凝集素SHL24，SHL24不被D-甘露糖、D-麦芽糖、葡萄糖、蔗糖、树胶醛糖、D-乳糖以及L-鼠李糖所抑制，具有较好的热稳定性且其凝血活性不受Ca2+、Mg2+和Zn2+等二价阳离子的影响，具有的稳定理化性质和生物活性，有作为蛋白质药物的潜质。此外桑黄的功效还包括降血糖、抗血管生成、抗氧化、抗菌、抗炎、抗诱变、抗突变、治疗关节炎等，主要用于预防或治疗癌症、糖尿病、关节炎、胃肠道功能紊乱、腹泻和过敏。
发明内容
本发明要解决的技术问题是提供一种桑黄水提物在抗尿酸中的应用。
所述的桑黄水提物主要包含质荷比为1015.0270、1029.2048道尔顿的两种物质，该两种物质质谱检测谱峰强度分别为60％和100％；该桑黄醇提物制备方法如下：
(1)取生长于长白山地区的桑黄打碎成粉末；
(2)将步骤(1)得到的桑黄粉末按照固液比为1:10(m/v)的比例加入水，搅拌均匀后，放在沸水浴中煮2h得到混合溶液；
(3)将步骤(2)得到的混合溶液取出冷却，超速离心，取上清；
(4)将上清进行过滤得桑黄水提物，121℃高压灭菌得到桑黄水提物。
本发明利用水将桑黄溶解，然后进行沸水浴加热，再通过超速离心方法获得桑黄水提物。通过采用关节局部造模的方法，建立高尿酸模型，研究桑黄水提物对尿酸水平的影响。实验证明，本发明的桑黄水提物与秋水仙碱相比，在减少关节腔中尿酸沉积方面效果更好，因此可以利用桑黄水提物降低体内的尿酸含量，以达到治疗痛风的目的。
附图说明
图1是本发明的桑黄水提物飞行时间质谱检测结果。
图2不同时间点大鼠的关节肿胀率的分析图。
具体实施方
下面结合具体实施方式对本发明进行进一步的详细描述，给出的实施例仅为了阐明本发明，而不是为了限制本发明的范围。
实施例1：桑黄水提物的制备
(1)取生长于长白山地区的桑黄打碎成粉末；
(2)称取一定量的桑黄粉末，按照1:10(m/v)的比例加入10倍体积的水，搅拌均匀后，放在沸水浴中煮2h得到混合溶液。
(3)取出混合溶液冷却，在4800rpm/min下超速离心15min，取上清。
(4)将上清进行过滤得桑黄水提物，121℃高压灭菌30min，4℃冰箱保存备用。
检测时，将步骤五得到的桑黄醇提物加入质谱检测仪，通过MALDI-TOF飞行时间质谱检测桑黄醇提液中所含物质种类及含量，检测结果见图1，质荷比为1015.0270、1029.2048道尔顿的两种物质相对强度较高，该两种物质质谱检测谱峰相对强度分别为60％和100％。
实施例2：大鼠高尿酸模型的建立
(1)7-8周龄Wistar大鼠8只，按照空白组(Control)、模型组(Model)、桑黄水提物组(Phelinus igniarius)、秋水仙碱阳性组(Colchicine)进行分组，每组2只鼠。
(2)建立模型之前对空白组和模型组灌喂超纯水，对桑黄水提物组和秋水仙碱组分别灌喂桑黄水提物和秋水仙碱，每组连续灌胃9天，每天灌胃一次，每次2mL。
(3)在灌胃的第6天建模。对空白组大鼠进行关节腔注射生理盐水100μL，模型组、桑黄水提物组和秋水仙碱组注射100μL浓度为30mg/mL的尿酸钠溶液。
实施例3：大鼠关节肿胀率的测定
在建模的第0h、4h、12h、24h、48h、72h和96h测量大鼠关节的周径，计算关节的肿胀率。[Swelling ratio＝(S1-S0)/S0；(S1为任意时间点的周径，S0为0h时的周径)]。
从图2中可以看出在0-24h，大鼠的关节肿胀率呈上升趋势，24-96h大鼠的关节肿胀率呈下降趋势，在72h时，大鼠的关节趋于正常，但是桑黄水提物组的大鼠关节肿胀率比其他组小，说明桑黄水提物能够显著减少关节腔中尿酸的沉积。
本发明利用水对桑黄活性成分进行提取，以灌胃的形式让大鼠食用。采用关节腔注射尿酸钠的方式建立局部高尿酸模型，持续灌喂大鼠桑黄水提物，在建模第0h、4h、12h、24h、48h、72h、96h测定大鼠的关节肿胀率以及在0h、4h、12h、24h、48h、96h取大鼠血样儿，测定大鼠血清中尿酸的含量，结果显示在注射尿酸钠溶液以后，大鼠的关节部位会出现红肿、发热的状况，随着时间的延长，这种现象会逐渐好转，根据测量：食用桑黄水提物的大鼠组关节的肿胀率明显下降，血清中尿酸的含量明显减少。
Claims (2)
1.一种桑黄水提物在抗尿酸中的应用。
2.根据权利要求1所述的桑黄水提物在抗尿酸中的应用，其特征在于所述的桑黄水提物主要包含质荷比为1015.0270、1029.2048道尔顿的两种物质，该两种物质质谱检测谱峰强度分别为60％和100％；该桑黄醇提物制备方法如下：
(1)取生长于长白山地区的桑黄打碎成粉末；
(2)将步骤(1)得到的桑黄粉末按照固液比为1:10(m/v)的比例加入水，搅拌均匀后，放在沸水浴中煮2h得到混合溶液；
(3)将步骤(2)得到的混合溶液取出冷却，超速离心，取上清；
(4)将上清进行过滤得桑黄水提物，121℃高压灭菌得到桑黄水提物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810370531.8A CN108379305A (zh) | 2018-04-24 | 2018-04-24 | 桑黄水提物在抗尿酸中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810370531.8A CN108379305A (zh) | 2018-04-24 | 2018-04-24 | 桑黄水提物在抗尿酸中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108379305A true CN108379305A (zh) | 2018-08-10 |
Family
ID=63064549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810370531.8A Pending CN108379305A (zh) | 2018-04-24 | 2018-04-24 | 桑黄水提物在抗尿酸中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108379305A (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110693921A (zh) * | 2019-11-18 | 2020-01-17 | 淳安千岛湖桑都食用菌专业合作社 | 一种人工栽培桑黄子实体的提取物及其制备方法和应用 |
| CN112189505A (zh) * | 2020-08-28 | 2021-01-08 | 徐州工程学院 | 一种治疗痛风的人工栽培桑黄子实体提取物及其制备方法 |
| CN114176212A (zh) * | 2021-12-06 | 2022-03-15 | 广东省农业科学院蚕业与农产品加工研究所 | 一种降尿酸提高免疫力火锅配料及其制备方法 |
| CN114190542A (zh) * | 2021-12-06 | 2022-03-18 | 广东省农业科学院蚕业与农产品加工研究所 | 一种降尿酸养生汤包料及其制备方法 |
| CN114832022A (zh) * | 2022-06-16 | 2022-08-02 | 湖北省农业科学院农产品加工与核农技术研究所 | 一种桑黄子实体酚类活性物质的制备及其在调节肠道菌群、尿酸代谢中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105876777A (zh) * | 2016-04-12 | 2016-08-24 | 周安琪 | 具有降低尿酸作用的食品及其制备工艺 |
-
2018
- 2018-04-24 CN CN201810370531.8A patent/CN108379305A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105876777A (zh) * | 2016-04-12 | 2016-08-24 | 周安琪 | 具有降低尿酸作用的食品及其制备工艺 |
Non-Patent Citations (2)
| Title |
|---|
| 王钦博等: "桑黄水提物抑菌作用的研究与应用 ", 《上海农业学报》 * |
| 陈若芸主编: "《中国食用药用真菌化学》", 31 March 2016, 上海科学技术文献出版社 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110693921A (zh) * | 2019-11-18 | 2020-01-17 | 淳安千岛湖桑都食用菌专业合作社 | 一种人工栽培桑黄子实体的提取物及其制备方法和应用 |
| CN110693921B (zh) * | 2019-11-18 | 2022-03-15 | 淳安千岛湖桑都食用菌专业合作社 | 一种人工栽培桑黄子实体的提取物及其制备方法和应用 |
| CN112189505A (zh) * | 2020-08-28 | 2021-01-08 | 徐州工程学院 | 一种治疗痛风的人工栽培桑黄子实体提取物及其制备方法 |
| CN114176212A (zh) * | 2021-12-06 | 2022-03-15 | 广东省农业科学院蚕业与农产品加工研究所 | 一种降尿酸提高免疫力火锅配料及其制备方法 |
| CN114190542A (zh) * | 2021-12-06 | 2022-03-18 | 广东省农业科学院蚕业与农产品加工研究所 | 一种降尿酸养生汤包料及其制备方法 |
| CN114832022A (zh) * | 2022-06-16 | 2022-08-02 | 湖北省农业科学院农产品加工与核农技术研究所 | 一种桑黄子实体酚类活性物质的制备及其在调节肠道菌群、尿酸代谢中的应用 |
| CN114832022B (zh) * | 2022-06-16 | 2023-09-15 | 湖北省农业科学院农产品加工与核农技术研究所 | 一种桑黄子实体酚类活性物质的制备及其在调节肠道菌群、尿酸代谢中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108379305A (zh) | 桑黄水提物在抗尿酸中的应用 | |
| Gong et al. | Supercritical CO2 fluid extraction, physicochemical properties, antioxidant activities and hypoglycemic activity of polysaccharides derived from fallen Ginkgo leaves | |
| JP2018538328A (ja) | 人参類サポニンを有効成分として含む組成物 | |
| Pitchaipillai et al. | In vitro antidiabetic activity of ethanolic leaf extract of bruguiera Cylindrica L.–glucose uptake by yeast cells method | |
| CN103073651B (zh) | 一种灵芝多糖的提取方法及应用 | |
| Mbaka et al. | Activity of Raphia hookeri root extract on blood glucose, lipid profile and glycosylated haemoglobin on alloxan induced diabetic rats | |
| KR100803998B1 (ko) | 진피발효추출물, 그 제조방법 및 건강기능식품 | |
| CN106474145A (zh) | 辣木叶多糖在制备防治酒精性肝损伤药物和食品中的应用 | |
| CN103479963A (zh) | 一种治疗类风湿关节炎的中药胶囊及其制备方法 | |
| CN110101731B (zh) | 具有防治眼部疾病的菊茎叶活性提取物及其制备方法与应用 | |
| CN105218695A (zh) | 一种黑果枸杞多糖提取物及其制备方法 | |
| Mohd et al. | Antidiabetic activity of the aqueous extract of Annona squamosa in Streptozotocin inducedhyperglycemic rats | |
| CN103961534A (zh) | 一种含虫草多糖生物制剂的制备方法 | |
| KR102181220B1 (ko) | 생약 추출물을 포함하는 항암용 약학적 조성물 | |
| KR20220020147A (ko) | 상황버섯균사체 추출물 또는 상황버섯균사체 추출물 분말의 제조방법 및 이들을 유효성분으로 포함하는 면역 증강용 조성물 | |
| KR101792875B1 (ko) | 홍삼 및 유산균을 함유하는 혈관질환을 예방, 개선 또는 치료하기 위한 조성물 | |
| CN117343210A (zh) | 一种具有抗炎活性的裂褶菌子实体多糖及其用途 | |
| Park et al. | Anti-diabetic effects of fermented Acanthopanax senticosus extracts on rats with streptozotocin-induced type 1 diabetic mellitus | |
| CN104004110A (zh) | 一种从瓜子金中提取的瓜子金多糖及其应用 | |
| CN104027363B (zh) | 一种从松木层孔菌中提取α‑葡萄糖苷酶抑制剂的方法 | |
| CN108567914A (zh) | 一种具有改善睡眠作用的中药制剂及其制备方法和应用 | |
| KR100778942B1 (ko) | 항염증 효과를 나타내는 소나무잔나비버섯 추출물 및 그용도 | |
| CN113730466A (zh) | 一种黑莓提取物的制备方法及其应用 | |
| CN102342962A (zh) | 马齿苋提取物在制备抗肝损伤药物及保健食品中的应用 | |
| CN102942634B (zh) | 一种韭菜籽中的多糖提取物及其提取方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180810 |
|
| RJ01 | Rejection of invention patent application after publication |